Atul Deshpande, Harbour BioMed chief strategy officer & head, US operations (Harbour BioMed)
July 9, 2020 07:00 AM EDTUpdated 10:14 AM
Financing
R&D

An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

Max Gelman

Senior Editor

A short four months af­ter an­nounc­ing a $75 mil­lion haul in Se­ries B+ fundrais­ing, the multi­na­tion­al biotech Har­bour Bio­Med pulled in an­oth­er round of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

A service from the Financial Times